KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Gross Margin (2018 - 2026)

Castle Biosciences' Gross Margin history spans 8 years, with the latest figure at 78.95% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 230.0% to 78.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 79.37%, a 250.0% decrease, with the full-year FY2025 number at 79.37%, down 250.0% from a year prior.
  • Gross Margin hit 78.95% in Q4 2025 for Castle Biosciences, up from 77.48% in the prior quarter.
  • Over the last five years, Gross Margin for CSTL hit a ceiling of 86.73% in Q1 2021 and a floor of 75.17% in Q4 2022.
  • Historically, Gross Margin has averaged 80.06% across 5 years, with a median of 80.9% in 2021.
  • Biggest five-year swings in Gross Margin: plummeted -886bps in 2022 and later surged 604bps in 2023.
  • Tracing CSTL's Gross Margin over 5 years: stood at 81.64% in 2021, then decreased by -8bps to 75.17% in 2022, then increased by 8bps to 81.21% in 2023, then rose by 0bps to 81.25% in 2024, then dropped by -3bps to 78.95% in 2025.
  • Business Quant data shows Gross Margin for CSTL at 78.95% in Q4 2025, 77.48% in Q3 2025, and 79.55% in Q2 2025.